<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31649034</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>294</Volume><Issue>49</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>High-throughput screening yields several small-molecule inhibitors of repeat-associated non-AUG translation.</ArticleTitle><Pagination><StartPage>18624</StartPage><EndPage>18638</EndPage><MedlinePgn>18624-18638</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.RA119.009951</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(20)30416-6</ELocationID><Abstract><AbstractText>Repeat-associated non-AUG (RAN) translation is a noncanonical translation initiation event that occurs at nucleotide-repeat expansion mutations that are associated with several neurodegenerative diseases, including fragile X-associated tremor ataxia syndrome (FXTAS), ALS, and frontotemporal dementia (FTD). Translation of expanded repeats produces toxic proteins that accumulate in human brains and contribute to disease pathogenesis. Consequently, RAN translation constitutes a potentially important therapeutic target for managing multiple neurodegenerative disorders. Here, we adapted a previously developed RAN translation assay to a high-throughput format to screen 3,253 bioactive compounds for inhibition of RAN translation of expanded CGG repeats associated with FXTAS. We identified five diverse small molecules that dose-dependently inhibited CGG RAN translation, while relatively sparing canonical translation. All five compounds also inhibited RAN translation of expanded GGGGCC repeats associated with ALS and FTD. Using CD and native gel analyses, we found evidence that three of these compounds, BIX01294, CP-31398, and propidium iodide, bind directly to the repeat RNAs. These findings provide proof-of-principle supporting the development of selective small-molecule RAN translation inhibitors that act across multiple disease-causing repeats.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Katelyn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109; Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan 48109.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheth</LastName><ForeName>Udit J</ForeName><Initials>UJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Brittany N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109; Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan 48109.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Shannon E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Alexandra B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kearse</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109; Department of Biological Chemistry and Pharmacology, Center for RNA Biology, Ohio State University, Columbus, Ohio 43210.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>Sami J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109; Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan 48109.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanova</LastName><ForeName>Magdalena I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109; Biophysics Program, University of Michigan, Ann Arbor, Michigan 48109.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Peter K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109; Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan 48109; Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan 48105. Electronic address: petertod@umich.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS097542</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS086810</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX003231</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>I21 BX001841</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS100302</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS096785</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS099280</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS089124</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007315</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C518299">BIX 01294</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>36015-30-2</RegistryNumber><NameOfSubstance UI="D011419">Propidium</NameOfSubstance></Chemical><Chemical><RegistryNumber>IN3WH41H3A</RegistryNumber><NameOfSubstance UI="C402665">CP 31398</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C564105">Fragile X Tremor Ataxia Syndrome</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Trends Pharmacol Sci. 2020 Feb;41(2):71-73</RefSource><PMID Version="1">31926601</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001259" MajorTopicYN="N">Ataxia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011419" MajorTopicYN="N">Propidium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014202" MajorTopicYN="N">Tremor</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">FXTAS</Keyword><Keyword MajorTopicYN="N">Lou Gehrig's disease</Keyword><Keyword MajorTopicYN="N">RAN translation</Keyword><Keyword MajorTopicYN="N">RNA</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease)</Keyword><Keyword MajorTopicYN="N">drug screening</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">small molecule</Keyword><Keyword MajorTopicYN="N">translation</Keyword></KeywordList><CoiStatement>P. K. T. served as a consultant with Denali Therapeutics, and he, K. M. G., and M. G. K. licensed technology through the University of Michigan to Denali Therapeutics that is based on the work published here</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31649034</ArticleId><ArticleId IdType="pmc">PMC6901296</ArticleId><ArticleId IdType="doi">10.1074/jbc.RA119.009951</ArticleId><ArticleId IdType="pii">S0021-9258(20)30416-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zu T., Gibbens B., Doty N. S., Gomes-Pereira M., Huguet A., Stone M. D., Margolis J., Peterson M., Markowski T. W., Ingram M. A., Nan Z., Forster C., Low W. C., Schoser B., Somia N. V., et al. (2011) Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. U.S.A. 108, 260&#x2013;265 10.1073/pnas.1013343108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1013343108</ArticleId><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd P. K., Oh S. Y., Krans A., He F., Sellier C., Frazer M., Renoux A. J., Chen K. C., Scaglione K. M., Basrur V., Elenitoba-Johnson K., Vonsattel J. P., Louis E. D., Sutton M. A., Taylor J. P., et al. (2013) CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 78, 440&#x2013;455 10.1016/j.neuron.2013.03.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.03.026</ArticleId><ArticleId IdType="pmc">PMC3831531</ArticleId><ArticleId IdType="pubmed">23602499</ArticleId></ArticleIdList></Reference><Reference><Citation>Krans A., Kearse M. G., and Todd P. K. (2016) Repeat-associated non-AUG translation from antisense CCG repeats in fragile X tremor/ataxia syndrome. Ann. Neurol 80, 871&#x2013;881 10.1002/ana.24800</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24800</ArticleId><ArticleId IdType="pmc">PMC5177492</ArticleId><ArticleId IdType="pubmed">27761921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P. E., Bieniek K. F., Gendron T. F., Caulfield T., Lin W. L., Dejesus-Hernandez M., van Blitterswijk M. M., Jansen-West K., Paul J. W. 3rd, Rademakers R., Boylan K. B., Dickson D. W., and Petrucelli L. (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 10.1016/j.neuron.2013.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S. M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H. A., Cruts M., Van Broeckhoven C., Haass C., and Edbauer D. (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 10.1126/science.1232927</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Arzberger T., Gr&#xe4;sser F. A., Gijselinck I., May S., Rentzsch K., Weng S. M., Schludi M. H., van der Zee J., Cruts M., Van Broeckhoven C., Kremmer E., Kretzschmar H. A., Haass C., and Edbauer D. (2013) Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 126, 881&#x2013;893 10.1007/s00401-013-1189-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1189-3</ArticleId><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T., Liu Y., Ba&#xf1;ez-Coronel M., Reid T., Pletnikova O., Lewis J., Miller T. M., Harms M. B., Falchook A. E., Subramony S. H., Ostrow L. W., Rothstein J. D., Troncoso J. C., and Ranum L. P. (2013) RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 110, E4968&#x2013;E4977 10.1073/pnas.1315438110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T., Cleary J. D., Liu Y., Ba&#xf1;ez-Coronel M., Bubenik J. L., Ayhan F., Ashizawa T., Xia G., Clark H. B., Yachnis A. T., Swanson M. S., and Ranum L. P. W. (2017) RAN translation regulated by muscleblind proteins in myotonic dystrophy type 2. Neuron 95, 1292&#x2013;1305.e5 10.1016/j.neuron.2017.08.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.08.039</ArticleId><ArticleId IdType="pmc">PMC5951173</ArticleId><ArticleId IdType="pubmed">28910618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ba&#xf1;ez-Coronel M., Ayhan F., Tarabochia A. D., Zu T., Perez B. A., Tusi S. K., Pletnikova O., Borchelt D. R., Ross C. A., Margolis R. L., Yachnis A. T., Troncoso J. C., and Ranum L. P. (2015) RAN translation in Huntington disease. Neuron 88, 667&#x2013;677 10.1016/j.neuron.2015.10.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.038</ArticleId><ArticleId IdType="pmc">PMC4684947</ArticleId><ArticleId IdType="pubmed">26590344</ArticleId></ArticleIdList></Reference><Reference><Citation>Buijsen R. A., Visser J. A., Kramer P., Severijnen E. A., Gearing M., Charlet-Berguerand N., Sherman S. L., Berman R. F., Willemsen R., and Hukema R. K. (2016) Presence of inclusions positive for polyglycine containing protein, FMRpolyG, indicates that repeat-associated non-AUG translation plays a role in fragile X-associated primary ovarian insufficiency. Hum. Reprod. 31, 158&#x2013;168 10.1093/humrep/dev280</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humrep/dev280</ArticleId><ArticleId IdType="pmc">PMC4677964</ArticleId><ArticleId IdType="pubmed">26537920</ArticleId></ArticleIdList></Reference><Reference><Citation>Soragni E., Petrosyan L., Rinkoski T. A., Wieben E. D., Baratz K. H., Fautsch M. P., and Gottesfeld J. M. (2018) Repeat-associated non-ATG (RAN) translation in Fuchs' endothelial corneal dystrophy. Invest. Ophthalmol. Vis. Sci. 59, 1888&#x2013;1896 10.1167/iovs.17-23265</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.17-23265</ArticleId><ArticleId IdType="pmc">PMC5886103</ArticleId><ArticleId IdType="pubmed">29677349</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquemont S., Hagerman R. J., Leehey M., Grigsby J., Zhang L., Brunberg J. A., Greco C., Des Portes V., Jardini T., Levine R., Berry-Kravis E., Brown W. T., Schaeffer S., Kissel J., Tassone F., and Hagerman P. J. (2003) Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am. J. Hum. Genet. 72, 869&#x2013;878 10.1086/374321</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/374321</ArticleId><ArticleId IdType="pmc">PMC1180350</ArticleId><ArticleId IdType="pubmed">12638084</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquemont S., Hagerman R. J., Leehey M. A., Hall D. A., Levine R. A., Brunberg J. A., Zhang L., Jardini T., Gane L. W., Harris S. W., Herman K., Grigsby J., Greco C. M., Berry-Kravis E., Tassone F., and Hagerman P. J. (2004) Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 291, 460&#x2013;469 10.1001/jama.291.4.460</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.4.460</ArticleId><ArticleId IdType="pubmed">14747503</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman R. J., Leehey M., Heinrichs W., Tassone F., Wilson R., Hills J., Grigsby J., Gage B., and Hagerman P. J. (2001) Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57, 127&#x2013;130 10.1212/WNL.57.1.127</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.1.127</ArticleId><ArticleId IdType="pubmed">11445641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C., Buijsen R. A. M., He F., Natla S., Jung L., Tropel P., Gaucherot A., Jacobs H., Meziane H., Vincent A., Champy M. F., Sorg T., Pavlovic G., Wattenhofer-Donze M., Birling M. C., et al. (2017) Translation of expanded CGG repeats into FMRpolyG is pathogenic and may contribute to fragile X tremor ataxia syndrome. Neuron 93, 331&#x2013;347 10.1016/j.neuron.2016.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.12.016</ArticleId><ArticleId IdType="pmc">PMC5263258</ArticleId><ArticleId IdType="pubmed">28065649</ArticleId></ArticleIdList></Reference><Reference><Citation>Buijsen R. A., Sellier C., Severijnen L. A., Oulad-Abdelghani M., Verhagen R. F., Berman R. F., Charlet-Berguerand N., Willemsen R., and Hukema R. K. (2014) FMRpolyG-positive inclusions in CNS and non-CNS organs of a fragile X premutation carrier with fragile X-associated tremor/ataxia syndrome. Acta Neuropathol. Commun. 2, 162 10.1186/s40478-014-0162-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0162-2</ArticleId><ArticleId IdType="pmc">PMC4254384</ArticleId><ArticleId IdType="pubmed">25471011</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., Boxer A. L., Baker M., Rutherford N. J., Nicholson A. M., Finch N. A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G. Y., Karydas A., et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A. E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J. R., Schymick J. C., Laaksovirta H., van Swieten J. C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A. M., Kaganovich A., et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D., O'Rourke J. G., Meera P., Muhammad A. K., Grant S., Simpkinson M., Bell S., Carmona S., Ornelas L., Sahabian A., Gendron T., Petrucelli L., Baughn M., Ravits J., Harms M. B., et al. (2013) Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 5, 208ra149 10.1126/scitranslmed.3007529</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Gr&#xf6;nke S., Niccoli T., Ridler C. E., Clayton E. L., Devoy A., Moens T., Norona F. E., Woollacott I. O. C., Pietrzyk J., Cleverley K., Nicoll A. J., Pickering-Brown S., Dols J., Cabecinha M., et al. (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192&#x2013;1194 10.1126/science.1256800</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1256800</ArticleId><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X., Tan W., Westergard T., Krishnamurthy K., Markandaiah S. S., Shi Y., Lin S., Shneider N. A., Monaghan J., Pandey U. B., Pasinelli P., Ichida J. K., and Trotti D. (2014) Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84, 1213&#x2013;1225 10.1016/j.neuron.2014.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.010</ArticleId><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I., Xiang S., Kato M., Wu L., Theodoropoulos P., Wang T., Kim J., Yun J., Xie Y., and McKnight S. L. (2014) Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345, 1139&#x2013;1145 10.1126/science.1254917</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1254917</ArticleId><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. J., Jansen-West K., Xu Y. F., Gendron T. F., Bieniek K. F., Lin W. L., Sasaguri H., Caulfield T., Hubbard J., Daughrity L., Chew J., Belzil V. V., Prudencio M., Stankowski J. N., Castanedes-Casey M., et al. (2014) Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 128, 505&#x2013;524 10.1007/s00401-014-1336-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1336-5</ArticleId><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>May S., Hornburg D., Schludi M. H., Arzberger T., Rentzsch K., Schwenk B. M., Gr&#xe4;sser F. A., Mori K., Kremmer E., Banzhaf-Strathmann J., Mann M., Meissner F., and Edbauer D. (2014) C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 128, 485&#x2013;503 10.1007/s00401-014-1329-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1329-4</ArticleId><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores B. N., Dulchavsky M. E., Krans A., Sawaya M. R., Paulson H. L., Todd P. K., Barmada S. J., and Ivanova M. I. (2016) Distinct C9orf72-associated dipeptide repeat structures correlate with neuronal toxicity. PLoS One 11, e0165084 10.1371/journal.pone.0165084</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0165084</ArticleId><ArticleId IdType="pmc">PMC5077081</ArticleId><ArticleId IdType="pubmed">27776165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearse M. G., Green K. M., Krans A., Rodriguez C. M., Linsalata A. E., Goldstrohm A. C., and Todd P. K. (2016) CGG repeat-associated non-AUG translation utilizes a cap-dependent scanning mechanism of initiation to produce toxic proteins. Mol. Cell 62, 314&#x2013;322 10.1016/j.molcel.2016.02.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.02.034</ArticleId><ArticleId IdType="pmc">PMC4854189</ArticleId><ArticleId IdType="pubmed">27041225</ArticleId></ArticleIdList></Reference><Reference><Citation>Green K. M., Glineburg M. R., Kearse M. G., Flores B. N., Linsalata A. E., Fedak S. J., Goldstrohm A. C., Barmada S. J., and Todd P. K. (2017) RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat. Commun. 8, 2005 10.1038/s41467-017-02200-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02200-0</ArticleId><ArticleId IdType="pmc">PMC5722904</ArticleId><ArticleId IdType="pubmed">29222490</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabet R., Schaeffer L., Freyermuth F., Jambeau M., Workman M., Lee C. Z., Lin C. C., Jiang J., Jansen-West K., Abou-Hamdan H., D&#xe9;saubry L., Gendron T., Petrucelli L., Martin F., and Lagier-Tourenne C. (2018) CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. Nat. Commun. 9, 152 10.1038/s41467-017-02643-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02643-5</ArticleId><ArticleId IdType="pmc">PMC5764992</ArticleId><ArticleId IdType="pubmed">29323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W., Wang S., Mestre A. A., Fu C., Makarem A., Xian F., Hayes L. R., Lopez-Gonzalez R., Drenner K., Jiang J., Cleveland D. W., and Sun S. (2018) C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2&#x3b1; phosphorylation. Nat. Commun. 9, 51 10.1038/s41467-017-02495-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02495-z</ArticleId><ArticleId IdType="pmc">PMC5754368</ArticleId><ArticleId IdType="pubmed">29302060</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I. R., Arzberger T., Kremmer E., Troost D., Lorenzl S., Mori K., Weng S. M., Haass C., Kretzschmar H. A., Edbauer D., and Neumann M. (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 126, 859&#x2013;879 10.1007/s00401-013-1181-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1181-y</ArticleId><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonobe Y., Ghadge G., Masaki K., Sendoel A., Fuchs E., and Roos R. P. (2018) Translation of dipeptide repeat proteins from the C9ORF72 expanded repeat is associated with cellular stress. Neurobiol. Dis. 116, 155&#x2013;165 10.1016/j.nbd.2018.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.05.009</ArticleId><ArticleId IdType="pmc">PMC6331062</ArticleId><ArticleId IdType="pubmed">29792928</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T., McAvoy K., Russell K., Wen X., Pang Y., Morris B., Pasinelli P., Trotti D., and Haeusler A. (2019) Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress. EMBO Mol. Med. 11, e9423 10.15252/emmm.201809423</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201809423</ArticleId><ArticleId IdType="pmc">PMC6365928</ArticleId><ArticleId IdType="pubmed">30617154</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z., Zhang Y., Gendron T. F., Bauer P. O., Chew J., Yang W. Y., Fostvedt E., Jansen-West K., Belzil V. V., Desaro P., Johnston A., Overstreet K., Oh S. Y., Todd P. K., Berry J. D., et al. (2014) Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83, 1043&#x2013;1050 10.1016/j.neuron.2014.07.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.07.041</ArticleId><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone R., Balendra R., Moens T. G., Preza E., Wilson K. M., Heslegrave A., Woodling N. S., Niccoli T., Gilbert-Jaramillo J., Abdelkarim S., Clayton E. L., Clarke M., Konrad M. T., Nicoll A. J., Mitchell J. S., et al. (2018) G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol. Med. 10, 22&#x2013;31 10.15252/emmm.201707850</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707850</ArticleId><ArticleId IdType="pmc">PMC5760849</ArticleId><ArticleId IdType="pubmed">29113975</ArticleId></ArticleIdList></Reference><Reference><Citation>Disney M. D., Liu B., Yang W. Y., Sellier C., Tran T., Charlet-Berguerand N., and Childs-Disney J. L. (2012) A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. ACS Chem. Biol. 7, 1711&#x2013;1718 10.1021/cb300135h</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cb300135h</ArticleId><ArticleId IdType="pmc">PMC3477254</ArticleId><ArticleId IdType="pubmed">22948243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari D., Swaroop M., Southall N., Huang W., Zheng W., and Usdin K. (2015) High-throughput screening to identify compounds that increase fragile X mental retardation protein expression in neural stem cells differentiated from fragile X syndrome patient-derived induced pluripotent stem cells. Stem Cells Transl. Med. 4, 800&#x2013;808 10.5966/sctm.2014-0278</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2014-0278</ArticleId><ArticleId IdType="pmc">PMC4479623</ArticleId><ArticleId IdType="pubmed">25999519</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisman-Shomer P., Cohen E., Hershco I., Khateb S., Wolfovitz-Barchad O., Hurley L. H., and Fry M. (2003) The cationic porphyrin TMPyP4 destabilizes the tetraplex form of the fragile X syndrome expanded sequence d(CGG)n. Nucleic Acids Res. 31, 3963&#x2013;3970 10.1093/nar/gkg453</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkg453</ArticleId><ArticleId IdType="pmc">PMC165968</ArticleId><ArticleId IdType="pubmed">12853612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamiri B., Reddy K., Macgregor R. B. Jr., and Pearson C. E. (2014) TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. J. Biol. Chem. 289, 4653&#x2013;4659 10.1074/jbc.C113.502336</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C113.502336</ArticleId><ArticleId IdType="pmc">PMC3931028</ArticleId><ArticleId IdType="pubmed">24371143</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearse M. G., Goldman D. H., Choi J., Nwaezeapu C., Liang D., Green K. M., Goldstrohm A. C., Todd P. K., Green R., and Wilusz J. E. (2019) Ribosome queuing enables non-AUG translation to be resistant to multiple protein synthesis inhibitors. Genes Dev. 33, 871&#x2013;885 10.1101/gad.324715.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.324715.119</ArticleId><ArticleId IdType="pmc">PMC6601509</ArticleId><ArticleId IdType="pubmed">31171704</ArticleId></ArticleIdList></Reference><Reference><Citation>Starck S. R., Jiang V., Pavon-Eternod M., Prasad S., McCarthy B., Pan T., and Shastri N. (2012) Leucine-tRNA initiates at CUG start codons for protein synthesis and presentation by MHC class I. Science 336, 1719&#x2013;1723 10.1126/science.1220270</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1220270</ArticleId><ArticleId IdType="pubmed">22745432</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofer N., Weisman-Shomer P., Shklover J., and Fry M. (2009) The quadruplex r(CGG)n destabilizing cationic porphyrin TMPyP4 cooperates with hnRNPs to increase the translation efficiency of fragile X premutation mRNA. Nucleic Acids Res. 37, 2712&#x2013;2722 10.1093/nar/gkp130</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkp130</ArticleId><ArticleId IdType="pmc">PMC2677883</ArticleId><ArticleId IdType="pubmed">19273535</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W. Y., Wilson H. D., Velagapudi S. P., and Disney M. D. (2015) Inhibition of non-ATG translational events in cells via covalent small molecules targeting RNA. J. Am. Chem. Soc. 137, 5336&#x2013;5345 10.1021/ja507448y</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja507448y</ArticleId><ArticleId IdType="pmc">PMC4856029</ArticleId><ArticleId IdType="pubmed">25825793</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebaugh J. L. (2011) Guidelines for accurate EC50/IC50 estimation. Pharm. Stat. 10, 128&#x2013;134 10.1002/pst.426</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.426</ArticleId><ArticleId IdType="pubmed">22328315</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada S. J., Skibinski G., Korb E., Rao E. J., Wu J. Y., and Finkbeiner S. (2010) Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 30, 639&#x2013;649 10.1523/JNEUROSCI.4988-09.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada S. J., Ju S., Arjun A., Batarse A., Archbold H. C., Peisach D., Li X., Zhang Y., Tank E. M., Qiu H., Huang E. J., Ringe D., Petsko G. A., and Finkbeiner S. (2015) Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Proc. Natl. Acad. Sci. U.S.A. 112, 7821&#x2013;7826 10.1073/pnas.1509744112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509744112</ArticleId><ArticleId IdType="pmc">PMC4485101</ArticleId><ArticleId IdType="pubmed">26056265</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores B. N., Li X., Malik A. M., Martinez J., Beg A. A., and Barmada S. J. (2019) An intramolecular salt bridge linking TDP43 RNA binding, protein stability, and TDP43-dependent neurodegeneration. Cell Rep. 27, 1133&#x2013;1150.e8 10.1016/j.celrep.2019.03.093</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.03.093</ArticleId><ArticleId IdType="pmc">PMC6499398</ArticleId><ArticleId IdType="pubmed">31018129</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M., Mitra S., Schweitzer E. S., Segal M. R., and Finkbeiner S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805&#x2013;810 10.1038/nature02998</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02998</ArticleId><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>